Company: SUPN
Filing Date: 2025-08-05
Form Type: 10-Q
Source: 0001356576-25-000055
Chunk: 104

Company: SUPERNUS PHARMACEUTICALS, INC.
Filing Date: 2025-08-05
Form: 10-Q
Item: Part I, Item 1
Chunk 104
---
2024, respectively. The decrease in both periods was primarily due to the decline in net product sales of APOKYN due to lower volume and decline in net product sales of Oxtellar XR and Trokendi XR due to generic erosion, partially offset by the increases in net product sales from Qelbree and GOCOVRI due to higher volume and higher price, and ONAPGO which was launched in the second quarter of 2025.

Adjustments related to prior year sales for the six months period ended June 30, 2025 is approximately 4% of net product sales. The majority of the adjustments is attributable to Qelbree, reflecting favorable actual returns experienced in 2025. As a result, the Company changed its estimated provision for product returns based on the most recent experience. Adjustments related to prior year sales for the six months period ended June 30, 2024 was approximately 2% of net product sales.  Refer to discussion Sales Deductions and Related Accruals below. 

Sales Deductions and Related Accruals

We record accrued product returns and accrued product rebates as current liabilities in Accrued product returns and rebates, on our condensed consolidated balance sheets. We record sales discounts as a reduction against Accounts receivable, net on the unaudited condensed consolidated balance sheets. Both amounts are generally affected by changes in gross product sales, changes in the provision for net product sales deductions, and the timing of payments/credits.

30

The following table provides a summary of activity with respect to accrued product returns and rebates and sales discounts during the periods indicated (dollars in thousands): Accrued Product Returns and RebatesProductReturnsProductRebatesSales DiscountsTotalBalance at December 31, 2024$53,375 $115,330 $12,347 $181,052 Provision related to:Current year sales7,269 207,558 34,034 248,861 Prior year sales(12,461)(69)40 (12,490)Total provision(5,192)207,489 34,074 236,371 Less: Actual payments/credits(2,159)(187,927)(33,656)(223,742)Balance at June 30, 2025$46,024 $134,892 $12,765 $193,681 

Accrued Product Returns and RebatesProductReturnsProductRebates